Expanding Your Long-Acting Injectable (LAI) Antipsychotic Medication Toolbox-Presentation Slides

Presentation Slides

Pdf Summary

This document provides information about long-acting injectable (LAI) antipsychotic medications, their administration, and considerations for selecting LAIs for individuals. The document is part of the Clinical Support System for Serious Mental Illness (CSS-SMI) initiative, funded by the Substance Abuse and Mental Health Services Administration (SAMHSA) and implemented by the American Psychiatric Association (APA).<br /><br />The document begins by introducing the faculty involved in the initiative and their relevant expertise. It also includes disclosures regarding any financial relationships or conflicts of interest.<br /><br />The learning objectives of the document are listed as follows:<br />1. Identify landmarks for injection sites for LAI antipsychotic medications.<br />2. Understand clinical considerations for individual patients when injecting at each anatomical site.<br />3. Demonstrate decision-making using knowledge of LAI antipsychotic medication options, patient variables, and injection site locations.<br /><br />The document provides information on specific LAI agents, including Abilify Asimtufii®, Perseris®, Rykindo®, Uzedy™, and more. It describes the indications, delivery vehicles, half-life, Tmax, and drug interactions of these agents. It also includes information on dosing, missed doses, and preparation and administration techniques for each LAI.<br /><br />The document highlights important clinical pearls for each LAI, such as reconstitution requirements, injection site preferences, and observation periods. It also provides a comparison of LAI agents in terms of injection volumes and sites.<br /><br />Considerations for selecting LAIs are discussed, including administration interval, injection site selection, patient preferences, and preparation techniques. The document emphasizes the importance of patient choice and involvement in medication selection to improve adherence.<br /><br />The document mentions additional resources available through the SMI Adviser website, such as the Long-Acting Injectable Center of Excellence, videos on administering LAIs, and a dose conversion tool.<br /><br />Overall, this document provides concise information on various LAI antipsychotic medications and their administration, as well as considerations for choosing the most suitable option for individuals.

Keywords

long-acting injectable

LAI antipsychotic medications

administration

selecting LAIs

Clinical Support System for Serious Mental Illness

learning objectives

LAI agents

preparation

observation periods

patient choice